These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Aspirin desensitization following endoscopic sinus surgery is effective in patients with nonsteroidal antiinflammatory drug exacerbated respiratory disease. Aydin Ö; Atmiş EÖ; Anadolu Y; Yorulmaz İ; Çelik GE J Asthma; 2023 Jun; 60(6):1131-1140. PubMed ID: 36218308 [TBL] [Abstract][Full Text] [Related]
24. Unique Effect of Aspirin Therapy on Biomarkers in Aspirin-exacerbated Respiratory Disease. A Prospective Trial. Cahill KN; Cui J; Kothari P; Murphy K; Raby BA; Singer J; Israel E; Boyce JA; Laidlaw TM Am J Respir Crit Care Med; 2019 Sep; 200(6):704-711. PubMed ID: 30978291 [No Abstract] [Full Text] [Related]
25. Urinary Leukotriene E4 as a Biomarker in NSAID-Exacerbated Respiratory Disease (N-ERD): a Systematic Review and Meta-analysis. Marquette M; Tailor BV; Calder PC; Curtis PJ; Loke Y; Wilson AM Curr Allergy Asthma Rep; 2022 Dec; 22(12):209-229. PubMed ID: 36374376 [TBL] [Abstract][Full Text] [Related]
27. Levels of eicosanoids in nasal secretions associated with nasal polyp severity in chronic rhinosinusitis. Nordström A; Jangard M; Svedberg M; Ryott M; Kumlin M Prostaglandins Leukot Essent Fatty Acids; 2022 Sep; 184():102474. PubMed ID: 35917595 [TBL] [Abstract][Full Text] [Related]
30. Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease. Laidlaw TM; Cutler AJ; Kidder MS; Liu T; Cardet JC; Chhay H; Feng C; Boyce JA J Allergy Clin Immunol; 2014 Jun; 133(6):1692-701.e3. PubMed ID: 24486071 [TBL] [Abstract][Full Text] [Related]
31. Prostaglandin, leukotriene, and lipoxin balance in chronic rhinosinusitis with and without nasal polyposis. Pérez-Novo CA; Watelet JB; Claeys C; Van Cauwenberge P; Bachert C J Allergy Clin Immunol; 2005 Jun; 115(6):1189-96. PubMed ID: 15940133 [TBL] [Abstract][Full Text] [Related]
32. COX-2: Where are we in 2003? - Specific cyclooxygenase-2 inhibitors and aspirin-exacerbated respiratory disease. Crofford LJ Arthritis Res Ther; 2003; 5(1):25-7. PubMed ID: 12716444 [TBL] [Abstract][Full Text] [Related]
33. Which non-steroidal anti-inflammatory drug (NSAID) is safer in patients with Non-steroids Exacerbated Respiratory Disease (N-ERD)? A single-center retrospective study. Çakmak ME Tuberk Toraks; 2022 Dec; 70(4):365-374. PubMed ID: 36537094 [TBL] [Abstract][Full Text] [Related]
34. Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper. Kowalski ML; Agache I; Bavbek S; Bakirtas A; Blanca M; Bochenek G; Bonini M; Heffler E; Klimek L; Laidlaw TM; Mullol J; Niżankowska-Mogilnicka E; Park HS; Sanak M; Sanchez-Borges M; Sanchez-Garcia S; Scadding G; Taniguchi M; Torres MJ; White AA; Wardzyńska A Allergy; 2019 Jan; 74(1):28-39. PubMed ID: 30216468 [TBL] [Abstract][Full Text] [Related]
35. An update on the management of aspirin-exacerbated respiratory disease. Lee JH; Jung CG; Park HS Expert Rev Respir Med; 2018 Feb; 12(2):137-143. PubMed ID: 29249187 [TBL] [Abstract][Full Text] [Related]
36. Lower serum 15-HETE level predicts nasal ILC2 accumulation during COX-1 inhibition in AERD. Badrani JH; Cavagnero K; Eastman JJ; Kim AS; Strohm A; Yan C; Deconde A; Zuraw BL; White AA; Christiansen SC; Doherty TA J Allergy Clin Immunol; 2023 Nov; 152(5):1330-1335.e1. PubMed ID: 37543185 [TBL] [Abstract][Full Text] [Related]
37. The role of eicosanoids in respiratory mucus hypersecretion. Lundgren JD; Shelhamer JH; Kaliner MA Ann Allergy; 1985 Jul; 55(1):5-8, 11. PubMed ID: 2990259 [TBL] [Abstract][Full Text] [Related]
38. Aspirin-exacerbated respiratory disease and current treatment modalities. Sakalar EG; Muluk NB; Kar M; Cingi C Eur Arch Otorhinolaryngol; 2017 Mar; 274(3):1291-1300. PubMed ID: 27538737 [TBL] [Abstract][Full Text] [Related]
39. Analgesics and asthma. Szczeklik A; Nizankowska E; Mastalerz L; Szabo Z Am J Ther; 2002; 9(3):233-43. PubMed ID: 11941383 [TBL] [Abstract][Full Text] [Related]